OTC Viagra coming to the UK … soon-ish

Prostate cancer patients in the UK may want to know (if they don’t already) that the erectile dysfunction drug sildenafil (Viagra) will become available as an “over the counter” or OTC drug called Viagra Connect early next year. … READ MORE …

Xtandi beats out Zytiga in NICE evaluation in the UK

According to an article this morning on the PharmaTimes web site,  Astellas has convinced the National Institute for Health and Care Excellence (NICE) to recommend coverage of enzalutamide (Xandi) in chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

NHS to stop covering cost of cabazitaxel for mCRPC as of November

As reported in a wide spectrum of media over the past few days (see here for example), on Friday last week the National Health Service announced that it would no longer cover the costs associated with use of cabazitaxel (Jevtana) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC) through the UK’s Cancer Drugs Fund — effective as of November 1, 2015. … READ MORE …

NICE recommends coverage of radium-223, but …

According to a recent report in Pharma Times, the National Institute for Health and Care Excellence (NICE) in the UK is recommending coverage of treatment with radium-223 dichoride (Xofigo) but has changed its mind about coverage of degarelix (Firmagon). … READ MORE …

Prostate cancer mortality rates in the UK drop by 21 percent

According to a report in the Daily Telegraph, Cancer Research UK is claiming that deaths from prostate cancer in the UK have drop by 20.8 percent during the 19-year period from 1991-93 to 2010-12. … READ MORE …

NICE approves coverage for enzalutamide by NHS

The National Institute for Health and Care Excellence (NICE) has issued final approval for coverage of treatment with enzalutamide (Xtandi) for men with metastatic, castrated-resistant prostate cancer (mCRPC) who have already received prior treatment with docetaxel-based chemotherapy. … READ MORE …

NHS to build two PBRT centers in the UK

Apparently the British National Health Service has decided to stump up £250 million (equivalent to US$380 million) to build two proton beam radiation therapy (PBRT) units in the UK. … READ MORE …